Bottom line
BBH vs SHPAX: the short answer
BBH (VanEck Biotech ETF) and SHPAX (Health & Biotechnology Portfolio) are quite different portfolios: only about 22% of their top holdings (by weight) are shared.
BBH is cheaper at 0.35% vs 3% — a difference of $265 a year per $10,000 invested.
Over five years, SHPAX returned +3.1% a year vs +2.7% for BBH (reporting dates differ).
SHPAX has a front-end sales load of up to 5.75%; the other does not.
Updated Nov 19, 2026
BBH vs SHPAX side by side
| BBH | SHPAX | |
|---|---|---|
| Type | ETF | Mutual fund |
| Fund family | VanEck | Saratoga Advantage |
| Category | Technology Sector | Technology Sector |
| Expense ratio | 0.35% | 3% |
| Annual cost per $10k | $35 | $300 |
| 10-yr cost on $10k (prospectus) | $443 | $3,702 |
| Max front load | None | 5.75% |
| 12b-1 fee | — | — |
| 1-yr return | +21.2% | −5.5% |
| 5-yr return (annualized) | +2.7% | +3.1% |
| 10-yr return (annualized) | +4.5% | +4.1% |
| Best quarter | +27.6% | +15.0% |
| Worst quarter | −18.2% | −13.0% |
| Net assets (fund) | $395.6M | $10.5M |
| Number of holdings | 25 | 29 |
| Portfolio turnover | 19% | 22% |
| Returns as of | Dec 31, 2025 | Dec 31, 2024 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | BBH | SHPAX | Difference |
|---|---|---|---|
| 2024 | −4.4% | +0.3% | −4.7% |
| 2023 | +3.9% | −0.4% | +4.2% |
| 2022 | −15.1% | +2.0% | −17.1% |
| 2021 | +11.8% | +16.7% | −4.9% |
| 2020 | +22.1% | +3.6% | +18.4% |
| 2019 | +25.8% | +16.2% | +9.6% |
| 2018 | −10.2% | −5.5% | −4.8% |
| 2017 | +16.6% | +12.0% | +4.7% |
| 2016 | −15.0% | −2.0% | −13.1% |
Source: Fund prospectus bar charts
Holdings overlap
6 of BBH's top 25 holdings also appear in SHPAX's top 25.
| Holding | BBH | SHPAX |
|---|---|---|
| Amgen Inc | 15.25% | 5.04% |
| Gilead Sciences Inc | 12.79% | 3.94% |
| Vertex Pharmaceuticals Inc | 9.10% | 3.36% |
| Regeneron Pharmaceuticals Inc | 6.21% | 3.93% |
| United Therapeutics Corp | 2.83% | 6.17% |
| Incyte Corp | 2.49% | 2.89% |
Source: SEC Form N-PORT
BBH top 10
- Amgen Inc — 15.25%
- Gilead Sciences Inc — 12.79%
- Vertex Pharmaceuticals Inc — 9.10%
- Regeneron Pharmaceuticals Inc — 6.21%
- Revolution Medicines Inc — 5.27%
- Argenx SE — 4.97%
- Natera Inc — 4.92%
- IQVIA Holdings Inc — 4.31%
- Alnylam Pharmaceuticals Inc — 3.83%
- Biogen Inc — 3.63%
SHPAX top 10
- Cardinal Health Inc — 6.44%
- Jazz Pharmaceuticals Plc — 6.19%
- United Therapeutics Corp — 6.17%
- Amgen Inc — 5.04%
- Mckesson Corp — 4.90%
- Lantheus Holdings Inc — 4.64%
- Exelixis Inc — 4.55%
- Novartis Ag — 4.50%
- Cencora Inc — 4.33%
- Gilead Sciences Inc — 3.94%
FAQ
What is the difference between BBH and SHPAX?
Which is cheaper, BBH or SHPAX?
Should I own both BBH and SHPAX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.